Roche News, Roche Quote, RHHBY Quote

Roche (OP:RHHBY) Delayed: 57.14 +0.36 (0.63%)

Prev. Close

$56.78

Today 6M 1Y 5Y

Open

$57.15

52 Wk High

$35.13

52 Wk Low

$28.10

Day High

$57.47

Day Low

$57.02

P/E

N/A

EPS

$0.00

Volume

2,686,825

Friends, Peers and Foes (?): RO, ROG, ROG:SW, ROP, CHGCY (more...)

ALERTS | RSS

Oct 16, 2026 01:00 AM FDA approves Genentech's Enspryng for thyroid eye disease
Oct 16, 2026 01:00 AM FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
Oct 10, 2026 05:40 PM Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
Oct 9, 2026 01:01 AM FDA approves Genentech's Tecentriq for stage III colon cancer
Oct 9, 2026 01:01 AM FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
Oct 7, 2026 01:00 AM Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRC
Oct 1, 2026 09:00 AM Flatiron Health's Breast Cancer Panoramic Dataset Surpasses One Million Patients, Enabling Real-World Research at Unprecedented Scale
Oct 1, 2026 07:00 AM Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends
Oct 1, 2026 02:00 AM Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions
Oct 1, 2026 01:00 AM Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine

Entities mentioned with RHHBY

View All Entities